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Abstract
Advances in genome sequencing and gene discovery have created opportunities to efficiently 
assess more genetic conditions than ever before. Given the large number of conditions that can be 
screened, the implementation of expanded carrier screening using genome sequencing will require 
practical methods of simplifying decisions about the conditions for which patients want to be 
screened. One method to simplify decision making is to generate a taxonomy based on expert 
judgment. However, expert perceptions of condition attributes used to classify these conditions 
may differ from those used by patients. To understand whether expert and patient perceptions 
differ, we asked women who had received preconception genetic carrier screening in the last 3 
years to fill out a survey to rate the attributes (predictability, controllability, visibility, and severity) 
of several autosomal recessive or X-linked genetic conditions. These conditions were classified 
into one of five taxonomy categories developed by subject experts (significantly shortened 
lifespan, serious medical problems, mild medical problems, unpredictable medical outcomes, and 
adult-onset conditions). A total of 193 women provided 739 usable ratings across 20 conditions. 
The mean ratings and correlations demonstrated that participants made distinctions across both 
attributes and categories. Aggregated mean attribute ratings across categories demonstrated logical 
consistency between the key features of each attribute and category, although participants 
perceived little difference between the mild and serious categories. This study provides empirical 
*Corresponding author contact information: Michael Leo, PhD, Kaiser Permanente Center for Health Research, 3800 N Interstate 
Ave., Portland, Oregon, 97227 USA, Phone: 503-528-3909 (office), Fax: 503-335-2424, Michael.C.Leo@kpchr.org. 
None of the authors has a conflict of interest to declare.
HHS Public Access
Author manuscript
Am J Med Genet A. Author manuscript; available in PMC 2017 March 01.
Published in final edited form as:
Am J Med Genet A. 2016 March ; 170(3): 574–582. doi:10.1002/ajmg.a.37477.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
evidence for the validity of our proposed taxonomy, which will simplify patient decisions for 
results they would like to receive from preconception carrier screening via genome sequencing.
Keywords
Gene carrier testing; genome sequencing; genetics; patient perceptions; genetic condition 
taxonomy
INTRODUCTION
Genetic carrier screening is routinely offered to average risk women for a small number of 
conditions, such as cystic fibrosis [American College of Medicine Genetics Board of 
[Directors 2004] and beta-thalassemia [Cao et al. 2002; Cousens et al. 2010], and offered in 
high-risk populations for conditions such as Tay-Sachs disease [Kaback 2001], Canavan 
disease, and familial dysautonomia. Rapid advances in genomic sequencing technologies 
may soon expand screening to a genome-wide scale and inform people about their carrier 
status for over 1000 autosomal recessive or X-linked conditions. The availability of 
commercial panels (e.g., Counsyl, Good Start, Pathway Genomics) that test for hundreds of 
known genetic variants or conditions is accelerating the debate on the utility of carrier 
screening on a wider scale, and sequencing for this purpose may become economically 
feasible. Even if assessing carrier status is not the primary purpose of sequencing, findings 
about carrier status can be made available.
The challenges and benefits of revising the current approach to carrier screening — by 
expanding carrier screening to include more conditions or by reporting carrier risks in the 
general population of individuals — must be thoughtfully considered. Currently, most 
carrier screening is targeted to high-risk individuals in response to the birth of an affected 
child to a near relative or to individuals with a high risk based on ancestry, and testing is 
focused on a small number of conditions. However, most genetic conditions are relatively 
rare, and the vast majority of people are not aware of them or have no first-hand experience 
with families affected by these conditions.
Thus, an important challenge of expanding carrier screening, in terms of the number of 
genetic conditions and types of populations, is how to communicate information about the 
test results of many conditions that could be part of the testing in a way that facilitates 
effective decision making by laboratories, health care providers, and patients alike. The 
American College of Medical Genetics guidelines on expanded carrier screening panels 
[Grody et al. 2013] suggests that patients should be able to opt in to receive results for 
conditions with mild or variable expression and to opt out of receiving results for high 
penetrance conditions. The genetic conditions may have technical names and their 
expression may be variable, making it difficult to describe their features to laypersons. For 
these reasons, it is challenging to consider how patients would decide what kinds of results 
they would want to receive from a significantly expanded carrier screening program.
Our team is conducting a trial of using genome sequencing for preconception carrier 
screening as part of the Clinical Sequencing Exploratory Research (CSER) program funded 
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by the National Human Genome Research Institute of the National Institute of Health. 
Patients desire choice in terms of what results they would like to receive, but there are three 
major barriers to making these types of decisions: 1) the sheer number of conditions from 
which to choose, 2) most conditions are so rare that patients are not familiar with them, and 
3) it is not feasible to describe each and every condition to patients in a way they would 
understand [Schneider et al. 2015]. To address the challenge of simplifying patient decisions 
about screening using genome or exome sequencing while preserving patient choice, we 
identified a range of genetic conditions and developed five taxonomy categories that might 
be meaningful to both patients and experts. This taxonomy was developed to provide a 
simple tool to allow patients to select among several categories of genetic conditions they 
would want to learn about as part of preconception reproductive planning. The taxonomy 
accomplishes this by reducing the number of decisions that would be made by asking a 
participant to choose from a small and manageable set of categories instead of among 
hundreds of conditions, and by describing the categories in terms that are familiar and 
understandable by patients.
We used input from experts on our study team and from lay focus group participants to 
develop a taxonomy that categorized conditions based on their likely impact on affected 
offspring: significantly shortened lifespan, serious medical problems, mild medical 
problems, unpredictable medical outcomes, and adult-onset conditions [Korngeibel et al. 
(submitted as a companion paper to this journal)]. All five categories have some face 
validity, but none is supported by empirical data from patients’ mental models on how 
genetic conditions should be categorized or how the attributes or likely impacts of different 
genetic conditions affect patients’ perceptions of the risk for having them. Other attributes of 
genetic conditions could influence patients’ desire for certain aspects of preconception 
screening, including the types of impairments associated with the conditions (e.g., physical, 
sensory, cognitive), how noticeable the effects of the conditions would be, how expensive it 
would be to raise a child with a given condition, or how undesirable it would be to have a 
child affected by a given condition.
Any decision aid that truly facilitates patient decision-making about expanded carrier 
screening will reflect the attributes of conditions that drive a patient’s decisions about 
whether the results are worth knowing. Risk is a useful heuristic for understanding whether 
people want to act to avoid potential hazards. Risk appraisals involve both rational and 
affective processes [Slovic et al. 2005]. Expert assessment of risk in genetics relies heavily 
on quantitative characteristics, such as probabilities of occurrence, mortality estimates, and 
costs. In contrast layperson appraisals of risk in the context of illness and other social and 
technological hazards are often driven by affective characteristics of risk, such as the dread 
and uncertainty associated with the hazard and the perceived extent to which the risk can be 
controlled [Loewenstein et al. 2001; Shepperd et al. 2013; Slovic 1999; Slovic 2000; Slovic 
et al. 1979; Zikmund-Fisher et al. 2010]. The relative importance of these affective 
characteristics can vary across people and hazards. Thus, layperson perceptions of risk often 
differ from expert perceptions, and it is important to understand what these differences are. 
Three decades of research into perceptions of social and technological hazards have honed 
methods to illuminate legitimate, multi-faceted, qualitative and affective considerations 
about risk that are typically omitted from expert assessments [Kraus and Slovik 1988; Slovic 
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2000; Slovic et al. 1980]. Our primary objective in this study was to use such methods to 
evaluate the qualitative dimensions involved in patients’ assessments of the risks associated 
with a variety of genetic conditions. We expected the data generated by the study 
participants to provide empirical support for the validity of the expert-developed taxonomy 
as a decision-aid for preconception carrier screening that would greatly improve the ability 
of patients to make informed and satisfactory decisions about the results they would like to 
receive.
METHODS
Initial Selection of Characteristics of Genetic Conditions
We convened a panel with expertise in genetic counseling, medical genetics, risk perception, 
anthropology, biostatistics, and bioethics to select a manageable subsample of genetic 
conditions to be rated by survey participants from the long list of conditions that are 
potentially identifiable through genome sequencing. By their nature, genetic conditions are 
multidimensional and, because we wanted to ensure that our sample included variability 
across a spectrum of conditions, we decided to specify those characteristics, rate various 
conditions according to those characteristics, and then sample from those conditions such 
that all of the characteristics were adequately represented.
The expert panel developed a list of 13 characteristics upon which to rate genetic conditions 
(Table I). Next, the genetic counselors and physicians on the panel independently nominated 
genetic conditions as examples of each characteristic at various levels. For instance, Wilson 
disease, Tay-Sachs disease, and carnitine palmitoyltransferase 1A (CPT 1A) deficiency were 
deemed good examples, respectively, of genetic conditions resulting in a mild level of 
physical impairment, shortened lifespan, and maternal risk during pregnancy. No attempt 
was made to consider more than one characteristic at a time or to exhaustively characterize 
any one genetic condition. Rather, the goal was simply to identify a sample of conditions 
from across the spectrum of possibilities that could, collectively, represent exemplars of the 
various characteristics of conditions that we believed would drive layperson perceptions of 
risk and impact of genetic conditions. Nominations were reviewed by the entire expert panel. 
Wherever possible, conflicting judgments were resolved by discussion; where resolution was 
not possible, the condition was excluded. We selected 20 genetic conditions for inclusion in 
our investigation.
Development of Taxonomy Categories
These 20 conditions were also categorized into the five categories used in our taxonomy: 
shortened lifespan, serious medical problems, mild medical problems, adult-onset 
conditions, and unpredictable medical problems (Table II). Our study used a return of results 
committee (RORC) — a panel of specialists in clinical and laboratory genetics, pediatrics, 
genetic counseling, and obstetrics; and were a separate group from the expert panel — to 
categorize individual conditions into the taxonomy. More information about the 
development of the categories and their definitions can be found in Korngeibel et al. 
(submitted as a companion paper to this journal).
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Genetic Condition Descriptions
The expert panel then developed descriptions for the 20 genetic conditions. We began with 
information available on the Counsyl website (www.counsyl.com) during the summer of 
2013. As a first pass, we modified these descriptions by removing statements about 
probability (e.g., “…affects roughly 1 in 50,000…”) as well as ethnic group susceptibilities 
(e.g., “…the condition is particularly common among people of Finnish and Saudi Arabian 
descent”), because we did not want these elements to influence the judgments of survey 
participants (e.g., if the respondent does not have the ethnic background mentioned in the 
description, then they may be less likely to be invested in the description). We also removed 
mechanistic information about the condition (e.g., “the pancreas normally secretes insulin in 
response to rising blood sugar”) and, for the sake of parity, we ensured that each condition 
name appeared only once in its description. Following this step, the text describing each 
condition was organized by (a) the nature of the condition, (b) how the condition is treated, 
and (c) what someone with this condition might expect to happen over the life course. Then, 
each condition description was reviewed and edited by members of the expert panel, 
individually and collectively. Essential information was described consistently for each 
condition, and added to the description by genetic counselors if it was absent from the 
Counsyl description. The study team ensured that the exemplary characteristics of each 
condition were clearly communicated within the text for each condition. No formal or 
informal testing of these descriptions (e.g., language level or clinical comprehensiveness) 
was undertaken. A complete set of the condition descriptions used for this study can be 
found in the online supplemental materials.
Survey Instrument
We developed a web-based survey to evaluate laypersons’ perceptions regarding the 
perceived attributes of a genetic condition, their feelings about it, and the effect of 
knowledge of an elevated risk for having a child with that condition would have on their 
pregnancy plan. Adults with a near-term interest in undergoing carrier screening for 
reproductive planning were recruited for this survey. We collected data on participants’ age 
and education level. To limit respondent burden, five versions of the survey were prepared, 
each covering four of the 20 selected genetic conditions. The conditions were distributed 
across surveys to be balanced in the familiarity and severity of the conditions presented. The 
conditions included in each version of the survey, as well as the order in which the 
conditions were presented, are provided in the online supplemental materials.
During the online survey, the participant was presented with descriptions of four conditions, 
one at a time, after which they responded to 20 questions using a 7-point Likert scale 
ranging from strongly disagree (1) to strongly agree (7). The participant was asked to rate 
four attributes for each condition: controllability (for example, by treatment, diet, education, 
or avoiding things like cigarettes or exposure to the sun), predictability, visibility, and 
severity. These four attributes represent the critical dimensions that likely most influence 
patient perceptions of risk, and with the exception of visibility were also essential 
characteristics used by the RORC in classifying the conditions into the taxonomy. The 
remaining 16 items focused on how the respondent would think she would feel if she had a 
child with this condition (e.g., anxious, angry), her desire and responsibility to have 
Leo et al. Page 5
Am J Med Genet A. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
knowledge regarding genetic risk, and intent to change plans for pregnancy based on a low 
or high increased likelihood of having a child with the condition. Finally, we asked the 
participant for an overall rating of the severity of the impact resulting from having a child 
with that condition and how well she understood the condition as described in the survey.
The survey questions were identical for each genetic condition. The text of the survey 
instrument is available in the online supplemental materials.
Survey Pilot Testing
The online survey was pilot tested in August 2013 by members of our study team and a 
convenience sample of adults unaffiliated with the study. We obtained and incorporated 
feedback about the survey instructions, condition descriptions, survey questions, online 
features of the survey instrument (e.g., navigation), and time required to complete the 
survey.
Data Collection
A total of 1,500 adult female Kaiser Permanente Northwest (KPNW) members (300 for each 
version of the survey) who had received preconception genetic testing in the preceding 3 
years (generally for cystic fibrosis screening) were recruited for the study via e-mail. The 
five versions of the survey were randomly assigned to participants. Surveys were closed 
when 40 completed responses had been collected for a given version or after 5 days online, 
whichever came first. Most of the responses (>75%) were received within 48 hours of the 
survey being made available. Some versions had a slight over-quota because respondents 
were not turned away if they happened to be actively working on the questions when the 
40th completed survey was submitted.
Participants who answered the questions for all four genetic conditions in their survey were 
compensated with a $10 gift card. The study was approved by the KPNW Institutional 
Review Board.
RESULTS
Data Cleaning
We obtained 812 condition ratings from survey participants. We excluded ratings if (1) 
responses to any of the 20 questions within a condition were missing (n=16), (2) there was 
little variance across the responses given all items within a condition (standard deviation 
<0.50; n=6), (3) the survey was filled out in <8 minutes, with the presumption that the 
condition description and items were not read fully (cutoff was based on pilot testing of the 
time required to go through the survey; n=37), and (4) the participant indicated that they did 
not understand the condition description by responding strongly disagree, disagree, slightly 
disagree, or neither agree or disagree to the first item (“The description of this condition was 
understandable”; n=14). The final sample sizes consisted of 193 participants and 739 
condition ratings. Because demographic characteristics are collected on KPNW members, 
we were able to compare those participants included in the analysis to the entire sample that 
were sent survey invitations on age, ethnicity, and race to determine whether there was any 
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response bias. There were no significant differences on age (mean difference=0.6 years, 95% 
CI [−0.2, 1.3] or race (χ2(1)=0.08, p=0.77). There were fewer Hispanic persons included in 
the analysis (3.9%) compared to the entire potential sample (9.6%), χ2(1)=4.41, p=0.04, but 
this difference was small and would not be significant if adjusted for multiple testing.
Demographic Characteristics
Seventy four (38%) respondents were between the ages of 30–34, 51 (26%) respondents 
were between 35–39 years, 29 (15%) respondents were between 40–44 years, 25 (13%) 
respondents were between 25–29 years and the remaining 14 (7%) chose not to answer or 
were adults outside the age range of 25–44 years. Eighty-four (44%) respondents reported 
having a graduate degree, 63 (33%) a bachelor’s degree, 34 (18%) some college or 
vocational school, and the remainder chose not to answer (4%) or had high school or GED 
(3%).
Descriptive Statistics
The means and standard deviations for each item by each of the 20 genetic conditions are 
presented in Table III. Respondents regarded Tay-Sachs disease (acute infantile form) and 
spinal muscular atrophy as the least controllable, highly predictable and visible, and the 
most severe conditions. Wilson disease was judged to be the most controllable, Gaucher 
disease type I the least predictable, alpha1-antitrypsin deficiency the least visible, and 
alkaptonuria the least severe. Of the four attributes, the controllable attribute had the most 
variability in ratings across participants.
The correlations among the attribute ratings are presented in Table IV. The correlations 
ranged from extremely low (r=.01 for severity and predictability) to moderate (r=−.31 for 
severity and controllability). The small correlations suggest that respondents perceived 
genetic conditions as having distinct combinations of attributes (controllable, predictable, 
visible, and severe).
Primary Analysis
A profile plot of the five categories mapped over the four attributes of primary interest is 
presented in Figure 1. This plot does not depict any temporal relationship between the data 
points; rather, the graph is intended to show whether the attributes that survey respondents 
ascribe to the conditions in each of our taxonomy categories are similar or different. With 
the exception of the serious and mild categories, the profiles of the five genetic condition 
categories were distinctive. The mild and serious conditions had a similar profile, although 
the serious conditions were rated as slightly more uncontrollable, unpredictable, severe, and 
slightly less visible. Participants rated conditions in the shortened lifespan category as the 
most uncontrollable, visible, and severe and the least unpredictable. The sole condition in 
the unpredictable category, Fanconi anemia C, was rated the highest for being the most 
unpredictable and highly uncontrollable compared with the other categories. Finally, the 
conditions in the adult-onset category were rated as the least severe compared with 
conditions in the four other categories.
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Figure 2 presents the same data represented in Figure 1 using individual bar charts, with the 
addition of 95% confidence intervals for the aggregated mean ratings. Based on the width of 
the confidence intervals, the adult onset category appeared to have the most variability in 
ratings. The five categories show clearly distinct patterns across the attributes, even allowing 
for the variation in responses. As noted previously, the observed patterns are most similar for 
the mild and severe categories.
DISCUSSION
Our primary objective in this study was to empirically validate an expert-derived taxonomy 
as a decision-aid for preconception carrier screening using participant ratings of critical 
attributes involved in making assessments of overall risk. As a decision-aid, the taxonomy 
promotes patient autonomy by providing prospective parents with the means by which they 
can to make informed decisions about their carrier status by selecting categories of 
information they wish to receive. Overall, participants were able to differentiate among 
genetic conditions by key attributes (controllability, predictability, visibility, and severity), as 
evident by the low correlations among attributes and the differences in mean ratings for each 
condition. These results suggest that we presented complicated information to patients in a 
way that allowed them to make meaningful distinctions among the conditions. Furthermore, 
the five-category taxonomy developed by our experts to classify genetic conditions seemed 
to align well with participants’ attribute ratings. For example, the condition classified by the 
RORC in the variable expression category was also the condition rated by participants as the 
least predictable and controllable. The agreement in expert and lay perceptions lends 
confidence to the validity of our taxonomy for classifying genetic conditions.
Participants had difficulty in distinguishing between mild and serious medical problems. 
During its deliberations, the RORC itself had the most trouble with classifying conditions 
into these two categories. Thus, creating a break in the severity continuum between mild and 
serious is challenging because the appraisal of severity may be more complex than we 
anticipated; especially if many conditions fall on the boundary between what is considered 
mild and serious. If that is the case, we will need to refine the criteria for serious and mild 
conditions.
This preliminary but empirical validation of our taxonomy as a tool for distinguishing 
meaningful categories of genetic conditions from both lay and expert perspectives was 
developed from a deliberate, iterative process of negotiating meaningful categories that 
reflect how potential users of this decision aid (patients, clinicians, and laboratory personnel) 
construe the effects of various types of genetic conditions (see companion paper).
Our taxonomy reflects the historical trajectory of the development of genetic testing and 
corresponds to the ongoing policy debates related to the expansion of the range of conditions 
for which genetic testing may be offered. Conditions that are significantly life shortening 
during childhood were the first targets of preconception and prenatal genetic testing in the 
1970s. Over time, testing has expanded to a broader range of conditions that are medical 
involved but in whom children are expected to become adults. The policy controversies, in 
the context of prenatal testing and pediatric testing, focus on the expansion to conditions that 
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are mild [Cox 2004; Silver and Warren 2006; Waalen and Beutler 2009], involve 
impairments such as those related to hearing or vision, do not manifest themselves until 
adulthood, or highly unpredictable in outcome. These uses are more controversial because 
the importance of such information is highly contingent on individual patient values 
[Wilfond and Goddard 2015]. Some people will want this information and others will not. 
Thus, our categorization of genetic conditions allows individuals to obtain information about 
the group of conditions that matter to them while avoiding information that would not be 
important to them. Offering choice for the results from genomic sequencing is also 
supported by a recent survey on the attitudes of genetics professionals, where 81% 
responded that patient preferences should guide the return of results [Yu et al. 2014]. 
Existing experience provides support for the broad categories that have been defined in this 
taxonomy.
Our current project is intended to provide prospective parents with additional information 
about their reproductive risks. However, carrier results may be secondary findings from 
clinical sequencing done for other reasons. The approach developed here could be applied to 
carrier results that are secondary findings. Additional empirical data about patient 
preferences in this context will be needed to assess the utility of this approach.
Limitations
The population we drew our sample from was predominantly of European Ancestry and all 
were insured, so the generalizability of the agreement between lay and expert ratings of 
genetic conditions may not hold in other populations. Nevertheless, KPNW members are 
generally representative of the Portland, Oregon area’s demographics and include about 20% 
of the area’s total population. Future work may include a more nationally representative 
sample and other ethnic and racial groups. Future studies should also evaluate men’s 
perceptions of genetic conditions.
Our sample was drawn from a population that represents the likely future users of carrier 
screening using genomic sequencing, as the study participants had recently received 
preconception carrier screening. Additional research should examine the perceptions of 
condition attributes and return of results effects of people affected by genetic conditions or 
their family members, as they may perceive attributes very differently than someone without 
knowledge of these conditions. Given the greater urgency and more limited options available 
in the prenatal context, it may be worthwhile to compare the perceptions for those 
undergoing preconception carrier screening versus prenatal carrier testing.
Only 20 of many possible genetic conditions were rated in this exercise, and some categories 
included more conditions than others. We suggest that future research include more 
conditions and ensure they are more representatively balanced across all categories. We 
could not do that in the current study because the development of the taxonomy occurred 
simultaneously with the development of the survey materials. Classification by experts of 
additional conditions into categories and the gathering of expert ratings on their attributes 
and comparing them to patient ratings may provide further insight into the perceptions of 
risk and impact that can drive decision-making about obtaining carrier screening results.
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The descriptions of the conditions that were used in the survey were brief and were not 
meant to capture the nuances and breadth of each condition. However, we may need to 
develop more meaningful and accurate information in these descriptions. For instance, we 
were surprised by how high phenylketonuria was rated on severity by the study participants, 
and suspect that the condition was weighed too heavily towards the description of the 
untreated phenotype and did not adequately portray the experience of a treated individual. 
Also, despite our best efforts to write the descriptions as factual and descriptive to minimize 
bias in participant ratings, it is possible that the descriptions were still inherently or 
subliminally directive. For this reason, we include the full text given to participants in the 
online supplemental materials so that readers may evaluate the descriptions themselves.
A final limitation of our study was that these evaluations of selected condition descriptions 
were hypothetical in that participants were not going to be tested for the conditions that were 
rated. Our ongoing trial, which is part of the CSER consortium, is examining the patient 
experience with genome sequencing for preconception carrier screening. We will record 
patient preferences for the categories of results they choose to receive for carrier screening 
as well as their satisfaction and regret with these decisions immediately after receiving the 
results and 3 months later. We will also examine the behaviors and reactions to the 
information that is returned to participants from genome sequencing as well as the 
downstream effects of and utilization from learning this information. The trial will provide 
greater insight into actual participant experiences, and we will gain a better understanding of 
participant preferences and decisions around carrier screening. All participants in this CSER 
study will have recently received preconception carrier screening as part of their usual 
medical care and thus will have a near term interest in learning and using this information 
for reproductive decision-making.
Conclusion
Genetic conditions rated by participants are logically consistent with the classification of 
conditions made by an expert panel using a newly created taxonomy of autosomal recessive 
and X-linked conditions. The results provide empirical evidence for the utility of the 
taxonomy for patients in making informed decisions on what categories of conditions they 
want to learn about for reproductive decision-making. In developing a taxonomy and 
empirically validating it in other clinical contexts where patients face an array of genetic 
testing options, both expert and lay perceptions should be considered to account for potential 
differences in their perspectives.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Profile Plot of mean aggregate participant ratings of the characteristics (controllability, 
predictability, severity, and visibility) for conditions in each taxonomy category
Conditions were categorized as described in Table III.
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Figure 2. Bar charts of mean and 95% confidence intervals for aggregate participant ratings of 
the characteristics (controllability, predictability, severity, and visibility) for conditions in each 
taxonomy category
Conditions were categorized as described in Table III.
Note: Unpredictable category does not have 95% CI because it contains only one condition.
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Table I
Characteristics of Genetic Conditions Identified by Expert Panel
Characteristic Categories
Physical impairment Mild; moderate; high
Cognitive impairment Mild; moderate; high
Sensory impairment Mild; moderate; high
Chronic pain Mild; moderate-severe
Requirements of daily care Low; moderate; high
Healthcare system interaction Low; moderate; high
Effectiveness of treatment Low; moderate; high
Care costs Low; moderate; high
Lifespan In years: 0–6; 7–20; 21–40; 41+; no effect
Infertility Male; female
Age of onset In years: 0–12; 13–21; 22+
Maternal risk during pregnancy Yes; no
Variability of expression Yes; no
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Table II
Description of taxonomy categories.
Taxonomy Category Description
Shortened Lifespan Most children do not live past early childhood, even with medical interventions.
Serious Medical Problems Most children will have medical problems that require regular medical visits, daily medications, 
carefully monitored diets, or surgeries; or will have serious problems with learning, vision, hearing or 
mobility.
Mild Medical Problems Most children will have medical problems that require occasional extra medical visits, occasional 
medications, a slightly modified diet, or surgery; or will have mild problems with learning, vision, 
hearing, or mobility.
Unpredictable Medical Outcomes The outcome is difficult to predict for many children, where some children will have more serious 
versions but others will have more mild versions or no problems at all.
Adult Onset Conditions Few have any symptoms as children, but medical, behavioral, vision, or hearing problems may begin as 
adults.
Am J Med Genet A. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Leo et al. Page 16
Ta
bl
e 
III
G
en
et
ic
 C
on
di
tio
n 
A
ttr
ib
u
te
 S
co
re
s, 
by
 T
ax
o
n
o
m
y 
Ca
te
go
ry
 (n
 = 
73
9 r
ati
ng
s)
C
on
tr
o
lla
bl
e
Pr
ed
ic
ta
bl
e
Vi
sib
le
Se
v
er
e
M
SD
M
SD
M
SD
M
SD
Sh
or
te
ne
d 
lif
es
pa
n
Sp
in
al
 m
us
cu
la
r a
tro
ph
y
1.
76
1.
84
5.
21
1.
56
6.
47
1.
36
6.
71
1.
34
Ta
y-
Sa
ch
s d
ise
as
e 
(ac
ute
 in
fan
til
e 
fo
rm
)
1.
89
1.
41
5.
97
1.
32
6.
35
0.
64
6.
68
0.
82
Se
rio
us
 m
ed
ic
al
 p
ro
bl
em
s
Co
he
n 
sy
nd
ro
m
e
3.
73
1.
26
4.
78
1.
07
6.
22
0.
82
5.
05
1.
06
B
lo
om
 sy
nd
ro
m
e
4.
39
1.
49
4.
68
1.
28
6.
32
1.
19
6.
13
1.
13
D
uc
he
nn
e 
m
us
cu
la
r d
ys
tro
ph
y
2.
72
1.
60
4.
79
1.
71
6.
18
1.
48
6.
41
1.
01
U
sh
er
 sy
nd
ro
m
e 
ty
pe
 1
F
2.
94
1.
70
5.
11
1.
19
5.
60
0.
70
5.
17
0.
81
Ph
en
yl
ke
to
nu
ria
5.
12
1.
75
4.
85
1.
18
5.
38
1.
03
6.
12
1.
25
W
ils
on
 d
ise
as
e
5.
92
1.
03
4.
89
1.
47
4.
53
1.
30
4.
58
1.
05
G
al
ac
to
se
m
ia
5.
76
1.
07
5.
21
1.
09
4.
59
1.
40
5.
06
1.
25
Cy
sti
c 
fib
ro
sis
4.
12
1.
19
4.
53
0.
93
3.
82
0.
56
5.
79
1.
38
Cl
as
sic
 h
em
op
hi
lia
 ty
pe
 A
4.
75
0.
84
4.
83
1.
12
4.
05
1.
46
6.
00
1.
40
CP
T 
IA
 d
ef
ic
ie
nc
y*
5.
86
0.
68
5.
39
1.
02
3.
47
1.
59
5.
06
1.
49
M
ild
 m
ed
ic
al
 p
ro
bl
em
s
H
yp
oh
id
ro
tic
 e
ct
od
er
m
al
 d
ys
pl
as
ia
5.
54
1.
65
5.
57
1.
33
6.
51
1.
66
5.
35
1.
17
A
ta
xi
a 
w
ith
 v
ita
m
in
 E
 d
ef
ic
ie
nc
y
5.
62
1.
77
4.
69
1.
29
5.
85
1.
41
5.
41
1.
36
A
ch
ro
m
ot
op
sia
3.
85
1.
33
5.
10
1.
65
4.
90
1.
57
4.
69
1.
53
U
np
re
di
ct
ab
le
 m
ed
ic
al
 o
ut
co
m
es
Fa
n
co
n
i a
ne
m
ia
 C
2.
59
1.
70
3.
26
1.
28
4.
06
1.
46
6.
12
1.
01
A
du
lt-
on
se
t c
on
di
tio
ns
A
lk
ap
to
nu
ria
4.
68
1.
82
5.
38
1.
58
5.
41
1.
80
1.
95
0.
88
A
lp
ha
1-
an
tit
ry
ps
in
 d
ef
ic
ie
nc
y
5.
50
1.
33
4.
33
1.
59
3.
28
0.
99
4.
78
1.
41
H
er
ed
ita
ry
 h
em
oc
hr
om
at
os
is
5.
63
1.
17
4.
50
1.
61
3.
95
0.
60
2.
65
0.
65
G
au
ch
er
 d
ise
as
e 
ty
pe
 I
3.
87
1.
88
2.
69
1.
32
3.
33
0.
63
4.
82
1.
51
*
In
 p
ra
ct
ic
e,
 C
PT
 IA
 d
ef
ic
ie
nc
y 
fa
lls
 in
 th
e 
sh
or
te
ne
d 
lif
es
pa
n 
ca
te
go
ry
 b
ec
au
se
 it
 is
 p
ot
en
tia
lly
 li
fe
 th
re
at
en
in
g 
to
 th
e 
m
ot
he
r c
ar
ry
in
g 
a 
ch
ild
 w
ith
 th
is 
co
nd
iti
on
. H
ow
ev
er
,
 
be
ca
us
e 
of
 th
e 
po
te
nt
ia
l i
m
pa
ct
 to
 
th
e 
m
ot
he
r, 
th
e 
Re
tu
rn
 o
f R
es
ul
ts 
Co
m
m
itt
ee
 c
on
sid
er
ed
 it
 im
po
rta
nt
 th
at
 a
ll 
pa
rti
ci
pa
nt
s r
ec
ei
v
e 
th
is 
in
fo
rm
at
io
n.
Am J Med Genet A. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Leo et al. Page 17
Table IV
Means, standard deviations, and Pearson correlations among participants attribute ratings of condition 
characteristics
Controllable Predictable Visible Severe
Controllable 4.31 (1.96)
Predictable
.10* 4.79 (1.52)
Visible
−.19* .30* 5.02 (1.66)
Severe
−.31* .01 .22* 5.22 (1.68)
*p<.01
Means and (standard deviations) are provided in the diagonal.
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